advertisement
11.13.4 Betablocker and prostaglandin (8)
Showing records 1 to 8
Display all abstracts in classification 11.13.4 Betablocker and prostaglandin
Search within classification 11.13.4 Betablocker and prostaglandin86205 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
Oddone F
Advances in Therapy 2020; 37: 1436-1451
86654 Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork
Tejwani S; Machiraju P
Journal of cellular and molecular medicine 2020; 24: 5195-5204
86205 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
Tanga L
Advances in Therapy 2020; 37: 1436-1451
86654 Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork
Nair AP
Journal of cellular and molecular medicine 2020; 24: 5195-5204
86205 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
Kóthy P; Holló G
Advances in Therapy 2020; 37: 1436-1451
86654 Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork
Ghosh A
Journal of cellular and molecular medicine 2020; 24: 5195-5204
86205 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
Advances in Therapy 2020; 37: 1436-1451
86654 Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork
Das RK; Sethu S
Journal of cellular and molecular medicine 2020; 24: 5195-5204
